Bavarian Nordic to Participate in European Midcap Event in Paris

24 juni 2014 KVISTGAARD, Denmark - June 24, 2014 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) announced today that Rolf Sass Sørensen, Vice President Investor Relations & Communications will participate in the European Midcap Event "Spring"  in Paris on June 26-27, 2014. The European Midcap Event is a 2-day event where listed companies from all over Europe meet with institutional investors. For more information, visit: http://www.midcapevents.com About Bavarian Nordic Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. IMVAMUNE is approved in the European Union under the trade name IMVANEX®. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit www.bavarian-nordic.com. Contacts Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43 This announcement is distributed by GlobeNewswire on behalf of GlobeNewswire clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Bavarian Nordic A/S via GlobeNewswire [HUG#1799270]